2-(3,4-Dichlorbenzyliden)-1-tetralon | 66045-84-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 2-(3,4-Dichlorbenzyliden)-1-tetralon
• 英文别名: (2E)-2-[(3,4-Dichlorophenyl)methylidene]-1,2,3,4-tetrahydronaphthalen-1-one；(2E)-2-[(3,4-dichlorophenyl)methylidene]-3,4-dihydronaphthalen-1-one
• CAS: 66045-84-9
• 化学式: C₁₇H₁₂Cl₂O
• 分子量: 303.188
• InChiKey: SNTMETDIRCPREC-UKTHLTGXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(3,4-Dichlorbenzyliden)-1-tetralon 在 盐酸 、 ammonium hydroxide 作用下， 以 甲醇 、 乙醇 、 水 为溶剂， 反应 39.0h， 生成 4-(3,4-dichlorophenyl)-5,6-dihydro-4H-benzo[h][3,1]benzothiazin-2-amine
  参考文献：
  名称：

  Lorand; Szabo; Foldesi, Pharmazie, 1984, vol. 39, # 8, p. 535 - 536

  摘要：

  DOI：
• 作为产物：
  描述：

  3,4-二氢-1(2H)-萘酮 、 3,4-二氯苯甲醛 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 生成 2-(3,4-Dichlorbenzyliden)-1-tetralon
  参考文献：
  名称：

  Tetralone derivatives are MIF tautomerase inhibitors and attenuate macrophage activation and amplify the hypothermic response in endotoxemic mice

  摘要：

  Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine playing crucial role in immunity. MIF exerts a unique tautomerase enzymatic activity that has relevance concerning its multiple functions and its small molecule inhibitors have been proven to block its pro-inflammatory effects. Here we demonstrate that some of the E-2-arylmethylene-1-tetralones and their heteroanalogues efficiently bind to MIF's active site and inhibit MIF tautomeric (enolase, ketolase activity) functions. A small set of the synthesised derivatives, namely compounds (4), (23), (24), (26) and (32), reduced inflammatory macrophage activation. Two of the selected compounds (24) and (26), however, markedly inhibited ROS and nitrite production, NF-κB activation, TNF-α, IL-6 and CCL-2 cytokine expression. Pre-treatment of mice with compound (24) exaggerated the hypothermic response to high dose of bacterial endotoxin. Our experiments suggest that tetralones and their derivatives inhibit MIF's tautomeric functions and regulate macrophage activation and thermal changes in severe forms of systemic inflammation.

  DOI：

  10.1080/14756366.2021.1916010

文献信息

• Intermolecular Reductive Cyclodimerization of Cyclic α,β-Unsaturated Ketones­ Promoted by a Low-Valent Titanium Reagent: A Facile Synthesis of Some New Spiro Compounds
  作者：Da-Qing Shi、Guo-Lan Dou、Zheng-Yi Li、Chun-Ling Shi、Xiao-Yue Li、Hong Jiang、Sai-Nan Ni、Shun-Jun Ji

  DOI：10.1055/s-2007-983707

  日期：2007.6

  β-unsaturated ketones such as 2-benzylideneindan-1-ones, 2-benzylidene-1 -tetralones, 3-benzylidenechroman-4-ones, and 3-benzylidenethiochroman-4-ones induced by a low-valent titanium reagent were studied. Some new spiro compounds were prepared in good yields under neutral and mild conditions. High stereoselectivity was achieved and the stereochemistry of the products was confirmed by X-ray diffraction

  α,β-不饱和酮如 2-benzylideneindan-1-ones、2-benzylidene-1-tetralones、3-benzylidenechroman-4-ones 和 3-benzylidenethiochroman-4-ones 的分子间还原环二聚反应对低价钛试剂进行了研究。一些新的螺环化合物在中性和温和条件下以高收率制备。实现了高立体选择性，并通过 X 射线衍射分析证实了产物的立体化学。
• Pharmaceutical compounds
  申请人：LILLY INDUSTRIES LIMITED

  公开号：EP0618206A1

  公开（公告）日：1994-10-05

  The invention provides pharmaceutical compounds of the formula: in which A --- B is CH₂-CH₂ or CH=CH; X is a pyridine or benzene ring; when X is pyridine n is 0; when X is benzene n is 0, 1 or 2 and when A --- B is CH₂-CH₂, R¹ is attached at any of the positions 7 to 10, and when A --- B is CH=CH, R¹ is attached at any of the positions 5 to 10; each R¹ is halo, carboxy, trifluoromethyl, hydroxy, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, hydroxy-C₁₋₄ alkyl, hydroxy-C₁₋₄ alkoxy, nitrogen-containing heterocyclyl, nitro, trifluoromethoxy, -COOR⁵ where R⁵ is an ester group, -COR⁶, -CONR⁶R⁷ or -NR⁶R⁷ where R⁶ and R⁷ are each hydrogen or C₁₋₄ alkyl; R² is phenyl, naphthyl or heteroaryl selected from thienyl, pyridyl, benzothienyl, quinolinyl, benzofuranyl or benzimidazolyl, said phenyl, naphthyl and heteroaryl groups being optionally substituted, or R² is furanyl optionally substituted with C₁₋₄ alkyl; R³ is nitrile, carboxy, -COOR⁸ where R⁸ is an ester group, -CONR⁹R¹⁰ where R⁹ and R¹⁰ are each hydrogen or C₁₋₄ alkyl, or -SO₂R¹¹ where R¹¹ is C₁₋₄ alkyl, optionally substituted phenyl or optionally substituted phenyl-C₁₋₄ alkyl; and R⁴ is 1-pyrrolyl, 1-imidazolyl or 1-pyrazolyl, said 1-pyrrolyl, 1-imidazolyl and 1-pyrazolyl being optionally substituted by one or two C₁₋₄ alkyl, carboxyl, hydroxy-C₁₋₄ alkyl or -CHO groups, or 1-(1,2,4-triazolyl), 1-(1,3,4-triazolyl) or 2-(1,2,3-triazolyl), said triazolyl groups being optionally substituted by a C₁₋₄ alkyl or C₁₋₄ perfluoroalkyl group, or 1-tetrazolyl optionally substituted by C₁₋₄ alkyl; and salts thereof.

  本发明提供了式中的药物化合物： 其中 A --- B 是 CH₂-CH₂ 或 CH=CH； X 是吡啶或苯环； 当 X 为吡啶时 n 为 0； 当X为苯时，n为0、1或2；当A--B为CH₂-CH₂时，R¹连接在7至10的任一位置；当A--B为CH＝CH时，R¹连接在5至10的任一位置； 每个 R¹ 是卤代、羧基、三氟甲基、羟基、C₁₋₄ 烷基、C₁₋₄ 烷氧基、C₁₋₄ 烷硫基、羟基-C₁₋₄ 烷基、羟基-C₁₋₄ 烷氧基、含氮杂环基、硝基、三氟甲氧基、-COOR⁵（其中 R⁵ 是酯基）、-COR⁶、-CONR⁶R⁷ 或-NR⁶R⁷（其中 R⁶ 和 R⁷ 各为氢或 C₁₋₄ 烷基）； R² 是苯基、萘基或选自噻吩基、吡啶基、苯并噻吩基、喹啉基、苯并呋喃基或苯并腙唑基的杂芳基，所述苯基、萘基和杂芳基被任选取代，或 R² 是被 C₁₋₄ 烷基任选取代的呋喃基； R³ 是腈、羧基、-COOR⁸（其中 R⁸ 是酯基）、-CONR⁹R¹⁰（其中 R⁹ 和 R¹⁰ 分别是氢或 C₁₋₄ 烷基）或-SO₂₋₄烷基、或-SO₂R¹¹，其中 R¹¹ 是 C₁₋₄烷基、任选取代的苯基或任选取代的苯基-C₁₋₄烷基；和 R⁴ 是 1-吡咯基、1-咪唑基或 1-吡唑基，所述 1-吡咯基、1-咪唑基和 1-吡唑基可任选被一个或两个 C₁₋₄烷基、羧基、羟基-C₁₋₄烷基或 -CHO 基团取代，或 1-(1,2、1-(1,2,3,4-三唑基)、1-(1,3,4-三唑基)或 2-(1,2,3-三唑基)，所述三唑基可选择被 C₁₋₄烷基或 C₁₋₄全氟烷基取代，或可选择被 C₁₋₄烷基取代的 1-四唑基； 及其盐类。
• 2-Substituted indazoles. Synthesis and antimicrobial activity
  作者：Tamás Lóránd、Béla Kocsis、Levente Emôdy、Pál Sohár

  DOI：10.1016/s0223-5234(99)00120-8

  日期：1999.11

  2-Isothiocarbamoyl substituted fused pyrazolines and their S-alkvl derivatives were prepared as potentially antimicrobial agents. Conventional methods were used to synthesize the novel derivatives starting from cyclic unsaturated ketones and thiosemicarbazide under acidic catalyst. These cyclizations yielded only one diastereoisomer of 3-H, 3a-H cis. The alkylations were performed applying alkyl halides. The structures of the new compounds, including configurations and conformations, were elucidated by NMR spectroscopy, also making use of 2D-HSC, DEFT and DNOE measurements. The S-alkyl derivatives were evaluated for activity against Gram-negative and Gram-positive bacteria and their in vitro toxicity was determined on HeLa cells. The structure-activity relationship was also studied. (C) 1999 Editions scientifiques et medicales Elsevier SAS.
• Deli, Jozsef; Lorand, Tamas; Foldesi, Andras, Acta Chimica Hungarica, 1984, vol. 117, # 3, p. 293 - 306
  作者：Deli, Jozsef、Lorand, Tamas、Foldesi, Andras、Szabo, Dezso、Prokai, Laszlo

  DOI：——

  日期：——
• LORAND, T.;SZABO, D.;FOELDESI, A.;OSSKE, G., PHARMAZIE, 1984, 39, N 8, 535-536
  作者：LORAND, T.、SZABO, D.、FOELDESI, A.、OSSKE, G.

  DOI：——

  日期：——